Literature DB >> 25572331

RAGE mediates S100A7-induced breast cancer growth and metastasis by modulating the tumor microenvironment.

Mohd W Nasser1, Nissar Ahmad Wani1, Dinesh K Ahirwar1, Catherine A Powell1, Janani Ravi1, Mohamad Elbaz1, Helong Zhao1, Laura Padilla2, Xiaoli Zhang3, Konstantin Shilo1, Michael Ostrowski4, Charles Shapiro1, William E Carson5, Ramesh K Ganju6.   

Abstract

RAGE is a multifunctional receptor implicated in diverse processes including inflammation and cancer. In this study, we report that RAGE expression is upregulated widely in aggressive triple-negative breast cancer (TNBC) cells, both in primary tumors and in lymph node metastases. In evaluating the functional contributions of RAGE in breast cancer, we found that RAGE-deficient mice displayed a reduced propensity for breast tumor growth. In an established model of lung metastasis, systemic blockade by injection of a RAGE neutralizing antibody inhibited metastasis development. Mechanistic investigations revealed that RAGE bound to the proinflammatory ligand S100A7 and mediated its ability to activate ERK, NF-κB, and cell migration. In an S100A7 transgenic mouse model of breast cancer (mS100a7a15 mice), administration of either RAGE neutralizing antibody or soluble RAGE was sufficient to inhibit tumor progression and metastasis. In this model, we found that RAGE/S100A7 conditioned the tumor microenvironment by driving the recruitment of MMP9-positive tumor-associated macrophages. Overall, our results highlight RAGE as a candidate biomarker for TNBCs, and they reveal a functional role for RAGE/S100A7 signaling in linking inflammation to aggressive breast cancer development. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25572331      PMCID: PMC4359968          DOI: 10.1158/0008-5472.CAN-14-2161

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases.

Authors:  A Taguchi; D C Blood; G del Toro; A Canet; D C Lee; W Qu; N Tanji; Y Lu; E Lalla; C Fu; M A Hofmann; T Kislinger; M Ingram; A Lu; H Tanaka; O Hori; S Ogawa; D M Stern; A M Schmidt
Journal:  Nature       Date:  2000-05-18       Impact factor: 49.962

Review 2.  Macrophage plasticity and polarization: in vivo veritas.

Authors:  Antonio Sica; Alberto Mantovani
Journal:  J Clin Invest       Date:  2012-03-01       Impact factor: 14.808

3.  Psoriasin (S100A7) expression and invasive breast cancer.

Authors:  S Al-Haddad; Z Zhang; E Leygue; L Snell; A Huang; Y Niu; T Hiller-Hitchcock; K Hole; L C Murphy; P H Watson
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 4.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

5.  RAGE gene deletion inhibits the development and progression of ductal neoplasia and prolongs survival in a murine model of pancreatic cancer.

Authors:  Joseph DiNorcia; Minna K Lee; Dorota N Moroziewicz; Megan Winner; Paritosh Suman; Fei Bao; Helen E Remotti; Yu Shan Zou; Shi Fang Yan; Wanglong Qiu; Gloria H Su; Ann Marie Schmidt; John D Allendorf
Journal:  J Gastrointest Surg       Date:  2011-11-04       Impact factor: 3.452

Review 6.  Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis.

Authors:  Armando Rojas; Hector Figueroa; Erik Morales
Journal:  Carcinogenesis       Date:  2009-12-22       Impact factor: 4.944

7.  Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis.

Authors:  Konstantin Shilo; Tatiana Dracheva; Haresh Mani; Junya Fukuoka; Isabell A Sesterhenn; Wei-Sing Chu; Joanna H Shih; Jin Jen; William D Travis; Teri J Franks
Journal:  Arch Pathol Lab Med       Date:  2007-10       Impact factor: 5.534

Review 8.  Global burden of cancers attributable to infections in 2008: a review and synthetic analysis.

Authors:  Catherine de Martel; Jacques Ferlay; Silvia Franceschi; Jérôme Vignat; Freddie Bray; David Forman; Martyn Plummer
Journal:  Lancet Oncol       Date:  2012-05-09       Impact factor: 41.316

Review 9.  RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation.

Authors:  Louis J Sparvero; Denise Asafu-Adjei; Rui Kang; Daolin Tang; Neilay Amin; Jaehyun Im; Ronnye Rutledge; Brenda Lin; Andrew A Amoscato; Herbert J Zeh; Michael T Lotze
Journal:  J Transl Med       Date:  2009-03-17       Impact factor: 5.531

10.  Specific siRNA targeting receptor for advanced glycation end products (RAGE) decreases proliferation in human breast cancer cell lines.

Authors:  Al-Madhagi Radia; Al-Madhagi Yaser; Xiaoqian Ma; Juan Zhang; Cejun Yang; Qiong Dong; Pengfei Rong; Bin Ye; Sheng Liu; Wei Wang
Journal:  Int J Mol Sci       Date:  2013-04-11       Impact factor: 5.923

View more
  56 in total

1.  Neutrophil Cathepsin G and Tumor Cell RAGE Facilitate Neutrophil Anti-Tumor Cytotoxicity.

Authors:  Ronit Vogt Sionov; Tanya Fainsod-Levi; Tamir Zelter; Lola Polyansky; Christine T Pham; Zvi Granot
Journal:  Oncoimmunology       Date:  2019-06-11       Impact factor: 8.110

Review 2.  DAMP-sensing receptors in sterile inflammation and inflammatory diseases.

Authors:  Tao Gong; Lei Liu; Wei Jiang; Rongbin Zhou
Journal:  Nat Rev Immunol       Date:  2019-09-26       Impact factor: 53.106

Review 3.  RAGE and Its Ligands: Molecular Interplay Between Glycation, Inflammation, and Hallmarks of Cancer-a Review.

Authors:  Gowri Palanissami; Solomon F D Paul
Journal:  Horm Cancer       Date:  2018-07-09       Impact factor: 3.869

4.  S100A7 has an oncogenic role in oral squamous cell carcinoma by activating p38/MAPK and RAB2A signaling pathway.

Authors:  K K Dey; R Bharti; G Dey; I Pal; Y Rajesh; S Chavan; S Das; C K Das; B C Jena; P Halder; J G Ray; I Kulavi; M Mandal
Journal:  Cancer Gene Ther       Date:  2016-10-21       Impact factor: 5.987

Review 5.  Hypoxia driven glycation: Mechanisms and therapeutic opportunities.

Authors:  Mohammad Imran Khan; Suvasmita Rath; Vaqar Mustafa Adhami; Hasan Mukhtar
Journal:  Semin Cancer Biol       Date:  2017-05-22       Impact factor: 15.707

Review 6.  S100A6 protein: functional roles.

Authors:  Rosario Donato; Guglielmo Sorci; Ileana Giambanco
Journal:  Cell Mol Life Sci       Date:  2017-04-17       Impact factor: 9.261

7.  Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis.

Authors:  T Kwak; K Drews-Elger; A Ergonul; P C Miller; A Braley; G H Hwang; D Zhao; A Besser; Y Yamamoto; H Yamamoto; D El-Ashry; J M Slingerland; M E Lippman; B I Hudson
Journal:  Oncogene       Date:  2016-09-26       Impact factor: 9.867

Review 8.  Scavenger Receptors: Emerging Roles in Cancer Biology and Immunology.

Authors:  Xiaofei Yu; Chunqing Guo; Paul B Fisher; John R Subjeck; Xiang-Yang Wang
Journal:  Adv Cancer Res       Date:  2015-06-17       Impact factor: 6.242

9.  Silencing of advanced glycosylation and glycosylation and product-specific receptor (RAGE) inhibits the metastasis and growth of non-small cell lung cancer.

Authors:  Yan Xia Yu; Wen Chong Pan; Yu Feng Cheng
Journal:  Am J Transl Res       Date:  2017-06-15       Impact factor: 4.060

Review 10.  The multiple faces of RAGE--opportunities for therapeutic intervention in aging and chronic disease.

Authors:  Ravichandran Ramasamy; Alexander Shekhtman; Ann Marie Schmidt
Journal:  Expert Opin Ther Targets       Date:  2015-11-11       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.